Back to results
US 11,439,643 B2Granted
Combination therapy using belinostat and pralatrexate to treat lymphoma
AssigneeAcrotech Biopharma Inc.
InventorGuru Reddy
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.
Claims5
A pharmaceutical composition, comprising:
- a first amount of belinostat;
- a second amount of pralatrexate;
- and
- a pharmaceutical carrier or excipient,
- wherein the first amount and the second amount comprise a therapeutically effective amount,
- wherein the therapeutically effective amount exhibits a synergistic growth inhibitory effect compared to the first amount alone or the second amount alone when used for the treatment of a mantle cell lymphoma, or a peripheral T-cell lymphoma, wherein the peripheral T-cell lymphoma is an anaplastic large cell lymphoma (ALCL) or a cutaneous T-cell lymphoma,
- wherein the therapeutically effective amount has a molar ratio of belinostat to pralatrexate of 8:1 when used for the treatment of the ALCL,
- wherein the therapeutically effective amount has a molar ratio of belinostat to pralatrexate of 5:1 when used for the treatment of the mantle cell lymphoma, and
- wherein the therapeutically effective amount has a molar ratio of belinostat to pralatrexate of 33:1 when used for the treatment of the cutaneous T-cell lymphoma.
6 more elements
Dependencies are inferred from the claim text.